On mice bearing PSMA‐positive prostate cancer xenografts, the biodistributions/dosimetry, tumor growth inhibition, and toxicities were evaluated for the same total injected radioactivity that was delivered by different split ratios between the two carriers. Here, FOLH1 is linked to prostate cancer.